Sesaminol prevents Parkinson's disease by activating the Nrf2-ARE signaling pathway

Haruka Kaji; Isao Matsui-Yuasa; Kayo Matsumoto; Ayano Omura; Kunio Kiyomoto; Akiko Kojima-Yuasa

doi:10.1016/j.heliyon.2020.e05342

Sesaminol prevents Parkinson's disease by activating the Nrf2-ARE signaling pathway

Heliyon. 2020 Nov 2;6(11):e05342. doi: 10.1016/j.heliyon.2020.e05342. eCollection 2020 Nov.

Authors

Haruka Kaji¹, Isao Matsui-Yuasa¹, Kayo Matsumoto¹, Ayano Omura², Kunio Kiyomoto², Akiko Kojima-Yuasa¹

Affiliations

¹ Department of Food and Human Health Sciences, Graduate School of Human Life Science, Osaka City University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka, 558-8585, Japan.
² Kiyomoto Co., Ltd., 6-1633 Totoro-cho, Nobeoka, Miyazaki, 889-0595, Japan.

Abstract

Parkinson's disease (PD) is a neurodegenerative disease caused by the degeneration of substantia nigra neurons due to oxidative stress. Sesaminol has strong antioxidant and anti-cancer effects. We investigated the preventive effect on PD as a new physiological action of sesaminol produced from sesaminol glycoside using in vitro and in vivo PD models. To prepare an in vitro PD model, 6-hydroxydopamine (6-OHDA) was added to human neuroblastoma (SH-SY5Y cells). The viability of SH-SY5Y cells decreased dose-dependently following 6-OHDA treatment, but the addition of sesaminol restored viability to the control level. 6-OHDA increased intracellular reactive oxygen species production, and the addition of sesaminol significantly suppressed this increase. No Nrf2 expression in the nucleus was observed in the control group, but a slight increase was observed in the 6-OHDA group. The sesaminol group showed strong expression of Nrf2 in the cytoplasm and nucleus. NAD(P)H: quinone oxidoreductase (NQO1) activity was enhanced in the 6-OHDA group and further enhanced in the sesaminol group. Furthermore, the neurotoxine rotenone was orally administrated to mice to prepare an in vivo PD model. The motor function of rotenone-treated mice was shorter than that of the control group, but a small amount of sesaminol restored it to the control level. The intestinal motility in the rotenone group was significantly lower than that in the control group, but it remained at the control level in the sesaminol group. The expression of α-synuclein in the substantia nigra increased in the rotenone group but decreased in the sesaminol group. The rotenone group exhibited shortening and damage to the colonic mucosa, but these abnormalities of the colonic mucosa were scarcely observed in the sesaminol group. These results suggest that sesaminol has a preventative effect on PD.

Keywords: 6-Hydroxydopamine; Antioxidant; Natural product; Neuroscience; Nrf2; Nutrition; Oxidative stress; Parkinson's disease; Rotenone; SH-SY5Y cells; Sesaminol.